文献速递前列腺癌

基因组风险分类器预测不良病理特征男性前列腺癌特异性死亡验证

Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
PubMed 文献 · Eur Urol · 2017-04-08

本研究在1987-2010年间于四家中心接受根治性前列腺切除术且具有不良病理特征的男性中验证22基因Decipher基因组分类器(GC)对前列腺癌特异性死亡(PCSM)的预测价值。中位随访13.0年,561例男性中112例发生10年内PCSM,高GC评分(>0.6)较低-中评分(≤0.6)经CAPRA-S校正后的OR为3.91(95%CI 2.43-6.29),AUC=0.77,较CAPRA-S提高0.04。

要点

  • 高GC评分(>0.6)较低-中评分(≤0.6)经CAPRA-S校正后PCSM10的OR为3.91(95%CI 2.43-6.29)。
  • GC预测PCSM10的AUC=0.77,较CAPRA-S提高0.04。
  • GC可将PCSM10累积发生率从2.8%分层至30%。

核心结论

  • 在具有不良病理特征、BCR2或MET的根治性前列腺切除术后男性中,Decipher GC可独立于CAPRA-S预测10年前列腺癌特异性死亡。

研究设计与样本

  • 验证22基因Decipher基因组分类器预测根治性前列腺切除术后不良病理特征男性PCSM的研究。
  • 纳入1987-2010年在约翰霍普金斯、克利夫兰诊所、梅奥诊所和达勒姆退伍军人事务医院接受根治性前列腺切除术的男性。
  • 不良病理特征定义为pT3、pN1、切缘阳性或Gleason评分>7。
  • 高风险亚组定义为前列腺特异性抗原>20 ng/ml、根治性前列腺切除术Gleason评分8-10或分期>pT3b。
  • 极高风险亚组定义为生化复发<2年(BCR2)或根治性前列腺切除术后发生转移(MET)。

主要发现

  • 高GC评分(>0.6)较低-中评分(≤0.6)经CAPRA-S校正后PCSM10的OR为3.91(95%CI 2.43-6.29)。
  • GC预测PCSM10的AUC=0.77,较CAPRA-S提高0.04。
  • 高风险、BCR2或MET亚组的OR分别为3.96、3.06和1.95(均p<0.05),AUC为0.64-0.72。
  • GC将PCSM10累积发生率从2.8%分层至30%。

临床怎么用

  • 原文结论指出,Decipher GC在具有不良病理特征、BCR2或MET的根治性前列腺切除术后男性中,对10年PCSM显示出具有临床意义的预测价值,且独立于CAPRA-S。
  • 患者摘要指出,Decipher基因组分类器可能改善根治性前列腺切除术后具有不良或高风险病理男性的治疗决策。

局限性

  • 病例对照与队列数据联合使用是潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk of prostate cancer-specific mortality (PCSM) is highly variable for men with adverse pathologic features at radical prostatectomy (RP); a majority will die of other causes. Accurately stratifying PCSM risk can improve therapy decisions. OBJECTIVE: Validate the 22 gene Decipher genomic classifier (GC) to predict PCSM in men with adverse pathologic features after RP. DESIGN, SETTING, AND PARTICIPANTS: Men with adverse pathologic features: pT3, pN1, positive margins, or Gleason score >7 who underwent RP in 1987-2010 at Johns Hopkins, Cleveland Clinic, Mayo Clinic, and Durham Veteran's Affairs Hospital. We also analyzed subgroups at high risk (prostate-specific antigen >20 ng/ml, RP Gleason score 8-10, or stage >pT3b), or very high risk of PCSM (biochemical recurrence in<2 yr [BCR2], or men who developed metastasis after RP [MET]). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic regression evaluated the association of GC with PCSM within 10 yr of RP (PCSM10), adjusted for the Cancer of the Prostate Risk Assessment Postsurgical Score (CAPRA-S). GC performance was evaluated with area under the receiver operating characteristic curve (AUC) and decision curves. RESULTS AND LIMITATIONS: Five hundred and sixty-one men (112 with PCSM10), median follow-up 13.0 yr (patients without PCSM10). For high GC score (> 0.6) versus low-intermediate (≤ 0.6), the odds ratio for PCSM10 adjusted for CAPRA-S was 3.91 (95% confidence interval: 2.43-6.29), with AUC=0.77, an increase of 0.04 compared with CAPRA-S. Subgroup odds ratios were 3.96, 3.06, and 1.95 for high risk, BCR2, or MET, respectively (all p<0.05), with AUCs 0.64-0.72. GC stratified cumulative PCSM10 incidence from 2.8% to 30%. Combined use of case-control and cohort data is a potential limitation. CONCLUSIONS: In a large cohort with the longest follow-up to date, Decipher GC demonstrated clinically important prediction of PCSM at 10 yr, independent of CAPRA-S, in men with adverse pathologic features, BCR2, or MET after RP. PATIENT SUMMARY: Decipher genomic classifier may improve treatment decision-making for men with adverse or high risk pathology after radical prostatectomy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Karnes RJ, Choeurng V, Ross AE, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2017. PMID: 28400167. doi:10.1016/j.eururo.2017.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。